These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 8854098

  • 1. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
    Mukhtar M, Duan L, Bagasra O, Pomerantz RJ.
    Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
    McAllister JJ, Phillips D, Millhouse S, Conner J, Hogan T, Ross HL, Wigdahl B.
    Virology; 2000 Sep 01; 274(2):262-77. PubMed ID: 10964770
    [Abstract] [Full Text] [Related]

  • 4. High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B.
    Negrini M, Rimessi P, Sabbioni S, Caputo A, Balboni PG, Gualandri R, Manservigi R, Grossi MP, Barbanti-Brodano G.
    Biotechniques; 1991 Mar 01; 10(3):344-53. PubMed ID: 1829615
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys.
    Brother MB, Chang HK, Lisziewicz J, Su D, Murty LC, Ensoli B.
    Virology; 1996 Aug 01; 222(1):252-6. PubMed ID: 8806505
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interactions between Marek's disease virus encoded or induced factors and the Rous sarcoma virus long terminal repeat promoter.
    Banders UT, Coussens PM.
    Virology; 1994 Feb 15; 199(1):1-10. PubMed ID: 8116231
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ribozyme targeting of HIV-1 LTR.
    Ventura M, Wang P, Franck N, Saragosti S.
    Biochem Biophys Res Commun; 1994 Sep 15; 203(2):889-98. PubMed ID: 8093072
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein.
    Zhang JL, Sharma PL, Crumpacker CS.
    Virology; 2000 Mar 15; 268(2):251-63. PubMed ID: 10704334
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G, Quinto I, Ruocco MR, Mallardo M, Ambrosino C, Squitieri B, Tassone P, Venuta S.
    J Virol; 1993 May 15; 67(5):2853-61. PubMed ID: 8386279
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.